Corrected: France's Advicenne swings to H1 net profit as revenue rises

Advicenne SA

17/09/2026 17:33

Corrects Key Details table and first Result Driver bullet to clarify the difference between current operating loss and operating income

Overview
France pharmaceutical firm's H1 net income turned positive, reversing prior yr loss
Revenue from ordinary activities grew 13% yr/yr, driven by Sibnayal and Likozam sales
Company withdrew U.S. marketing application for ADV7103, citing need for additional CMC work

Outlook
Advicenne expects continued strong sales growth in Europe and the Middle East in H2 2026
Company anticipates a significant reduction in operating expenses in H2 2026
Advicenne sees conclusion of safeguard observation period in November 2026 as a key milestone

Result Drivers
NON-RECURRING ITEMS - Co reported an operating income, benefiting from a reversal of provision and compensation for Likozam early access rebates after pricing agreements; excluding these, the company posted a smaller current operating loss
FRANCE SALES GROWTH - Co said accelerating volume growth for Sibnayal and Likozam in France, following pricing agreements, drove product sales
ROYALTY INCREASE - Co said royalties from Sibnayal distributors in Europe and Middle East rose 45%, contributing to revenue growth

Company press release: ID:nBw2sJShqa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Net Income
 
EUR 4.6 mln
 
H1 Current Operating Loss
 
EUR 1.6 mln
 
H1 Operating Income
 
EUR 5.5 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Advicenne SA is €4.00, about 478.9% above its September 16 closing price of €0.69

Reuters Recommended Reads
Sept 17 - Healthcare firm Ramsay Generale de Sante sees 2027 revenue rising by up to 3%
Sept 17 - Exosens lifts full-year forecasts again on speedy capacity ramp-up
Sept 14 - Contineum, J&J's depression drug fails to meet mid-stage trial goal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)